In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

“Multiplicative” Benefit of Cholesterol and Blood Pressure-Lowering on Cardiovascular Risk

Diabetes and the Heart
Basic Science
Risk Factors and Prevention

Rome, Italy – 29 Aug. 2016: Long-term exposure to the combination of even modestly lower LDL cholesterol (LDL-C) and systolic blood pressure (SBP) has the potential to “dramatically reduce” a person’s lifetime risk of cardiovascular disease, according to new findings reported at ESC Congress 2016.

The results, presented in a Hot Line session here, “demonstrate for the first time that LDL cholesterol and SBP have independent, multiplicative, and cumulative causal effects on the risk of cardiovascular disease,” said the study’s lead investigator Brian Ference MD, from Wayne State University School of Medicine, in Detroit.

“This suggests that a simple strategy that encourages long-term exposure to the combined reduction of both one mmol/L in LDL-C and 10 mmHg SBP has the potential to “largely eliminate” the lifetime risk of cardiovascular disease – with a reduction of up to 90%,” he explained.

The study used genetic and cardiovascular risk factor data from 102,773 individuals who had participated in 14 prospective cohort or case-control studies.

Investigators calculated genetic scores for each patient based on inherited polymorphisms known to be associated of LDL-C or SBP and the number of alleles associated with raised LDL-C or SBP levels.

Participants were then divided into 4 groups: the reference group, a group with an LDL-C genetic score below the median (resulting in lower LDL-C), a group with a SBP genetic score below the median (resulting in lower SBP), and a group with both LDL-C and SBP genetic scores below the median (resulting in both lower LDL-C and lower SBP).

The researchers then looked at the cardiovascular risk associated with the different genetic scores, with the primary outcome being a composite of the first occurrence of either coronary death, non-fatal myocardial infarction (MI), non-fatal stroke, or coronary revascularization.

There were 14,368 primary outcome events among the subjects.

Compared to the reference group, subjects in the lower LDL-C group had 54.2% lower risk of the primary outcome (OR 0.458), those in the lower SBP group had 44.7% lower risk (OR 0.553), and those in the combined lower LDL-C and SBP group had 86.1% lower risk (OR 0.139).

“The results of our study confirm that cardiovascular disease is largely preventable and suggest that this prevention can be substantially simplified by focusing on programs that promote longterm exposure to the combination of both lower LDL and lower SBP,” concluded Dr. Ference. He added that “further study is needed to identify who might benefit most from this type of early intervention.”


Notes to editor

Sources of funding: none

Disclosures: Dr Ference reports receiving research grants from Merck, Amgen, and Esperion Therapeutics; and consulting fees from Merck, Amgen, Esperion, and Ionis Pharmaceuticals.

ESC Press Office
For background information, please contact the ESC Press Office.

For press enquiries, please contact, the Media & Press Coordinator, Jacques Olivier Costa: +393427028575 

For independent comment on site, please contact the ESC Spokesperson coordinator, Celine Colas: +393402405148 

The press conference timetable is available here. 

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 120 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2016

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2016 takes place 27 to 31 August at the Fiera di Roma in Rome, Italy. The scientific programme is here. More information is available from the ESC Press Office at

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2016. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.